CorMedix Inc. (CRMD)
NASDAQ: CRMDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CRMD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $419.16M
- P/E (TTM)
- 8.23
- Forward P/E
- 15.06
- EPS (TTM)
- $0.64
- Dividend yield
- None
- 52-week range
- 4.47 – 13.02
- Day range
- 4.95 – 5.32
- Volume / Avg
- 3.61M / 1.44M
- Beta
- —
- Shares outstanding
- 79.54M
52-week range
CRMD stock today
CorMedix (CRMD) closed at $5.27 on Nov 20, up 3.74% (+$0.19), versus the S&P 500's 3.70% decline. Volume was 2.5x the average at 3.61M shares, a sign of unusually heavy trading. At this level, CRMD sits near the bottom of its 52-week range of $4.47 to $13.02: 59.5% below the high, set on Dec 30, 2025 and 17.9% above the low.
CRMD is down 54.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 45.6%. CorMedix trades at 8.2x its trailing twelve-month earnings per share of $0.64. Its forward P/E of 15.1x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About CorMedix
Company profileCorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Joseph Todisco MBA
- Headquarters
- Parsippany, NJ
- Employees
- 191
- Website
- cormedix.com
Financial highlights
Full financialsIn fiscal 2025, CorMedix generated $311.7 million in revenue, up 617.0% from fiscal 2024. Net income was $163.1 million, for a net margin of 52.3% versus a median of -11991.2% in the prior 5 years. Gross margin was 88.5% (down from 92.7%) and operating margin 48.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $311.71M | $43.47M | — | $65.41K | $190.94K |
| Growth | +617.03% | — | — | -65.74% | -20.19% |
| Net income | $163.06M | $-17.93M | $-46.34M | $-29.70M | $-28.21M |
| EPS (diluted) | $2.04 | $-0.30 | $-0.91 | $-0.74 | $-0.75 |
Analyst forecast
ForecastConsensus (5 analysts)
buy
Avg. price target
$13.80+161.86%
- Strong buy 3
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.04 vs $-0.09
- Surprise
- +55.56%
CRMD news
All CRMD news- Wednesday 11/18 Insider Buying Report: CRMD, PRAANasdaqCRMD, PRAA
- CorMedix Inc. Reports Q3 2026 Financial Results and Details Pending Heron Therapeutics AcquisitionNasdaq
- Weekly Buzz: LLY, JNJ Win FDA Nod; SION, NNOX, Cut Jobs; PFE, ARGX Strike DealsNasdaqAMGN, ARGX, AZN, BEAM
- CorMedix Inc. Reports Third Quarter 2026 Financial ResultsNasdaq
- CorMedix (CRMD) Q3 2026 Earnings Call TranscriptNasdaqCRMD, WSO.B
- CorMedix (CRMD) Reports Q3 Loss, Tops Revenue EstimatesNasdaqCRMD, TECH
- Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- CRMD to Acquire HRTX Assets for $223M Upfront to Expand PortfolioNasdaqCRMD, TGTX, HRTX, AMRX
CorMedix peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PRTAProthena Corporation plc | 8.22 | -2.14% | $422.10M | vs CRMD |
| ARVNArvinas Inc. | 6.46 | -4.15% | $423.03M | vs CRMD |
| OVIDOvid Therapeutics Inc. | 2.20 | -5.98% | $415.21M | vs CRMD |
| EOLSEvolus Inc. | 6.52 | -6.86% | $431.55M | vs CRMD |
| INDPIndaptus Therapeutics Inc. | 2.82 | -9.90% | $433.16M | vs CRMD |
| AQSTAquestive Therapeutics Inc. | 3.46 | -6.61% | $434.88M | vs CRMD |
| CAPRCapricor Therapeutics Inc. | 7.59 | +0.80% | $441.30M | vs CRMD |
| LYELLyell Immunopharma Inc. | 13.80 | +1.62% | $441.82M | vs CRMD |
Indexes, lists and sector
CorMedix stock FAQ
What is CorMedix's stock price today?
CRMD last traded at $5.27 as of Nov 20, 4:00 PM EST, up 3.74% on the day. Prices are delayed at least 15 minutes.
Does CorMedix pay a dividend?
No. CorMedix does not currently pay a regular cash dividend.
What is CRMD's P/E ratio?
CRMD trades at a trailing P/E ratio of 8.23 and a forward P/E of 15.06.
Who is CorMedix's CEO?
Mr. Joseph Todisco MBA is the chief executive officer of CorMedix Inc., which has about 191 employees.
Has CRMD ever split its stock?
Yes. The most recent CRMD stock split was a 1-for-5 split on Mar 26, 2019.
What is the CRMD 52-week high?
The 52-week high for CRMD is $13.02 and the 52-week low is $4.47. The stock is currently 59.5% below its high.